Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0496 | 0.1119 | 0.5 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0456 | 0 | 0.5 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.0776 | 0.8881 | 1 |
Brugia malayi | nuclear hormone receptor | 0.0776 | 0.8881 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0496 | 0.1119 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AUC (ADMET) | = 3.06 ug hr ml-1 | Compound was evaluated for Area under curve in mice | ChEMBL. | 2918517 |
AUC (ADMET) | = 3.06 ug hr ml-1 | Compound was evaluated for Area under curve in mice | ChEMBL. | 2918517 |
MIC (functional) | = 0.4 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (vogel) | ChEMBL. | 3005575 |
MIC (functional) | = 0.4 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (vogel) | ChEMBL. | 3005575 |
MIC (functional) | = 0.8 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (H560) | ChEMBL. | 3005575 |
MIC (functional) | = 0.8 ug ml-1 | Antibacterial activity against Klebsiella pneumonia (MGH-2) | ChEMBL. | 3005575 |
MIC (functional) | = 0.8 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (H560) | ChEMBL. | 3005575 |
MIC (functional) | = 0.8 ug ml-1 | Antibacterial activity against Klebsiella pneumonia (MGH-2) | ChEMBL. | 3005575 |
MIC (functional) | = 1.6 ug ml-1 | Antibacterial activity of the compound against Staphylococcus aureus (H228) | ChEMBL. | 3005575 |
MIC (functional) | = 1.6 ug ml-1 | Antibacterial activity of the compound against Staphylococcus aureus (H228) | ChEMBL. | 3005575 |
MIC (functional) | = 6.3 ug ml-1 | Antibacterial activity of the compound against Pseudomonas aeruginosa (UI-18) | ChEMBL. | 3005575 |
MIC (functional) | = 6.3 ug ml-1 | Antibacterial activity of the compound against Streptococcus pneumoniae (SV-1) | ChEMBL. | 3005575 |
MIC (functional) | = 6.3 ug ml-1 | Antibacterial activity of the compound against Pseudomonas aeruginosa (UI-18) | ChEMBL. | 3005575 |
MIC (functional) | = 6.3 ug ml-1 | Antibacterial activity of the compound against Streptococcus pneumoniae (SV-1) | ChEMBL. | 3005575 |
MIC (functional) | = 10 ug ml-1 | MIC of the compound at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 microg/mL by using Gyrase Induced DNA-Cleavage assay | ChEMBL. | 3005575 |
MIC (functional) | = 10 ug ml-1 | MIC of the compound at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 microg/mL by using Gyrase Induced DNA-Cleavage assay | ChEMBL. | 3005575 |
Serum concentration (functional) | = 0.29 | Serum concentration of the liberated Norfloxacin after oral administration of the compound 100 mg/kg in mice after the 0.5 h | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.63 | Serum concentration of the liberated Norfloxacin after oral administration of the compound 100 mg/kg in mice after the 4.0 h | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.75 | Serum concentration of the liberated Norfloxacin after oral administration of the compound 100 mg/kg in mice after the 1.0 h | ChEMBL. | 2918517 |
Serum concentration (functional) | = 1.15 | Serum concentration of the liberated Norfloxacin after oral administration of the compound 100 mg/kg in mice after the 2.0 h | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.29 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 0.5 hr | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.29 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 0.5 hr | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.63 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 4.0h | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.63 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 4.0h | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.75 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 1.0 hr | ChEMBL. | 2918517 |
Serum concentration (functional) | = 0.75 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 1.0 hr | ChEMBL. | 2918517 |
Serum concentration (functional) | = 1.15 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 2.0 hr | ChEMBL. | 2918517 |
Serum concentration (functional) | = 1.15 hr | Serum concentration of the liberated Norfloxacin after oral administration of the compound (100 mg/kg) in mice after 2.0 hr | ChEMBL. | 2918517 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.